Concord Drugs Intrinsic Value
Concord Drugs (CONCORD) median intrinsic value is ₹40.00 from 8 valuation models (range ₹24–₹80), vs current price ₹80.00 — -50.0% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit Concord Drugs share price today.
CONCORD Valuation Methods Summary — DCF, Graham Number & P/E
Concord Drugs intrinsic value across 8 models vs current price ₹80.00 — upside/downside and value range per method. Browse CONCORD financial statements for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹24.00 | ₹19.20 - ₹28.80 | -70.0% | EPS: ₹0.76, Sector P/E: 22x |
| Book Value Method | asset | ₹68.00 | ₹61.20 - ₹74.80 | -15.0% | Book Value/Share: ₹34.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹80.00 | ₹72.00 - ₹88.00 | 0.0% | Revenue/Share: ₹40.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹40.00 | ₹36.00 - ₹44.00 | -50.0% | EBITDA: ₹4.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹54.33 | ₹43.46 - ₹65.20 | -32.1% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹24.00 | ₹21.60 - ₹26.40 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹24.00 | ₹21.60 - ₹26.40 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹24.11 | ₹21.70 - ₹26.52 | -69.9% | EPS: ₹0.76, BVPS: ₹34.00 |
CONCORD Intrinsic Value vs Market Price — All Valuation Models
Concord Drugs fair value range ₹24–₹80 vs current market price ₹80.00 across 8 valuation models. Also explore Concord Drugs share price performance to track price trends across different timeframes.
CONCORD Intrinsic Value Analysis — Undervalued or Overvalued?
Concord Drugs median intrinsic value ₹40.00, current price ₹80.00 — Trading Above Calculated Value by 50.0%, margin of safety -100.0%.
What is the intrinsic value of CONCORD?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Concord Drugs (CONCORD) is ₹40.00 (median value). With the current market price of ₹80.00, this represents a -50.0% variance from our estimated fair value.
The valuation range spans from ₹24.00 to ₹80.00, indicating ₹24.00 - ₹80.00.
Is CONCORD undervalued or overvalued?
Based on our multi-method analysis, Concord Drugs (CONCORD) appears to be trading above calculated value by approximately 50.0%.
CONCORD Financial Health — Key Ratios vs Industry Benchmarks
Concord Drugs financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 8.20 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Operating Margin | 11.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.62x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
CONCORD Cash Flow Quality — Operating & Free Cash Flow
Concord Drugs operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹4 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹2 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹1 Cr | ₹0 Cr | Positive Operating Cash Flow | 6/10 |